Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal

Clinical Endocrinology

Volumn 76, Issue 5, 2012, Pages 734-740

  Cherk, Martin H ^a,b   Francis, Peter ^a   Topliss, Duncan J ^a,b   Bailey, Michael ^b   Kalff, Victor ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROID HORMONE;

ABLATION THERAPY; ADULT; ANALYZER; ARTICLE; CAMERA; CANCER STAGING; COLLIMATOR; DRUG UPTAKE; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; IMMUNOASSAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SERUM; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; WHOLE BODY SCINTISCANNING;

AUTOANTIBODIES; CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THYROGLOBULIN; THYROID HORMONES; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN ALFA;

EID: 84859640857     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04278.x     Document Type: Article

References (23)

1. Schlumberger, M., Berg, G., Cohen, O. et al. (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology/European Federation of Endocrine Societies, 150, 105-112.
2. Pacini, F., Capezzone, M., Elisei, R. et al. (2002) Diagnostic 131- iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism, 87, 1499-1501.
3. Pacini, F., Schlumberger, M., Dralle, H. et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology/European Federation of Endocrine Societies, 154, 787- 803.
4. Mazzaferri, E.L., Robbins, R.J., Spencer, C.A. et al. (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 88, 1433-1441. (Pubitemid 36623351)
5. Pellegriti, G., Scollo, C., Regalbuto, C. et al. (2003) The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clinical Endocrinology, 58, 556-561. (Pubitemid 36566797)
6. Park, E.K., Chung, J.K., Lim, I.H. et al. (2009) Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. European Journal of Nuclear Medicine and Molecular Imaging, 36, 172-179.
7. Lim, D.J., O, J.H., Kim, M.H. et al. (2010) Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin. The Korean Journal of Internal Medicine, 25, 408-414.
8. Ma, C., Kuang, A., Xie, J. et al. (2005) Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. Journal of Nuclear Medicine, 46, 1473-1480. (Pubitemid 46173259)
9. Zucchelli, G., Iervasi, A., Ferdeghini, M. et al. (2009) Serum thyroglobulin measurement in the follow-up of patients treated for differentiated thyroid cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 53, 482-489.
10. Grant, S., Luttrell, B., Reeve, T. et al. (1984) Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer, 54, 1625-1628.
11. Muller-Gartner, H.W. & Schneider, C. (1988) Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer, 61, 976-981.
12. Schlumberger, M., Hitzel, A., Toubert, M.E. et al. (2007) Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism, 92, 2487-2495. (Pubitemid 47037347)
13. Spencer, C.A. & Lopresti, J.S. (2008) Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nature Clinical Practice Endocrinology & Metabolism, 4, 223-233. (Pubitemid 351430907)
14. Preissner, C.M., O'Kane, D.J., Singh, R.J. et al. (2003) Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. Journal of Clinical Endocrinology and Metabolism, 88, 3069-3074. (Pubitemid 36877474)
15. Spencer, C., Petrovic, I. & Fatemi, S. (2011) Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 96, 1283-1291.
16. Morgenthaler, N.G., Froehlich, J., Rendl, J. et al. (2002) Technical evaluation of a new immunoradiometric and a new immunoluminometric assay for thyroglobulin. Clinical Chemistry, 48, 1077- 1083.
17. Bachelot, A., Cailleux, A.F., Klain, M. et al. (2002) Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid, 12, 707- 711.
18. Spencer, C.A., LoPresti, J.S., Fatemi, S. et al. (1999) Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid, 9, 435-441. (Pubitemid 29244919)
19. Bachelot, A., Leboulleux, S., Baudin, E. et al. (2005) Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. Clinical Endocrinology, 62, 376-379. (Pubitemid 40380422)
20. Kim, E.Y., Kim, W.G., Kim, W.B. et al. (2010) Clinical outcomes of persistent radioiodine uptake in the neck shown by diagnostic whole body scan in patients with differentiated thyroid carcinoma after initial surgery and remnant ablation. Clinical Endocrinology, 73, 257-263.
21. Rosario, P.W., Salles, D.S. & Purisch, S. (2009) Area under the curve of TSH after levothyroxine withdrawal versus administration of recombinant human TSH (rhTSH): possible implications for tumor growth. Arquivos brasileiros de endocrinologia e metabologia, 53, 767-770.
22. Haugen, B.R., Pacini, F., Reiners, C. et al. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism, 84, 3877-3885. (Pubitemid 30644169)
23. Ladenson, P.W., Braverman, L.E., Mazzaferri, E.L. et al. (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. The New England Journal of Medicine, 337, 888-896. (Pubitemid 27408571)